Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

Wolf-Karsten Hofmann1, Michael Lübbert, Dieter Hoelzer

  • 1Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA. W.K.Hofmann@em.uni-frankfurt.de

The Hematology Journal : the Official Journal of the European Haematology Association
|January 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.

Bone marrow transplantation·2025
Same author

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Leukemia & lymphoma·2025
Same author

Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet.

The Lancet. Haematology·2025
Same author

Management of ALL in adults: 2024 ELN recommendations from a European expert panel.

Blood·2024
Same author

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.

Blood·2024
Same author

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment.

Scientific reports·2023

Myelodysplastic syndromes (MDS) are clonal disorders impacting blood cell production. Current treatments focus on risk-adapted strategies, with future hope in targeted small molecules and immunomodulatory agents.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
  • Characterized by ineffective hematopoiesis, leading to cytopenias or acute myelogenous leukemia (AML).
  • Significant advancements in understanding MDS biology and prognosis over the past 15 years.

Purpose of the Study:

  • To review the current understanding and treatment strategies for Myelodysplastic syndromes.
  • To highlight the challenges in treating elderly MDS patients.
  • To discuss future therapeutic directions for MDS.

Main Methods:

  • Review of recent scientific literature on Myelodysplastic syndromes.
  • Analysis of established risk-adapted treatment strategies.
  • Discussion of current and emerging therapeutic modalities.

Related Experiment Videos

Main Results:

  • Risk-adapted treatment strategies have been developed considering patient age and disease characteristics.
  • Allogeneic bone marrow transplantation offers a potential cure but is often unsuitable for older patients.
  • Small molecule therapies and immunomodulatory agents represent promising future treatments.

Conclusions:

  • MDS treatment requires individualized, risk-adapted approaches.
  • Curative options like bone marrow transplant are limited for the typical elderly MDS patient.
  • Future research focuses on targeted therapies and optimizing existing treatments for better outcomes in MDS.